Egg ladder could help babies beat egg allergy at home
NCT ID NCT06273605
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tested a home-based, dietitian-led 'egg ladder' for infants newly diagnosed with egg allergy. Over 12 months, babies gradually ate more cooked egg, starting with baked goods. The goal was to see if this approach is safe and feasible. 109 infants participated, and researchers tracked allergic reactions and how well families followed the plan.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- egg ladder (gradual introduction of egg in cooked forms)
- What this could lead to
- If successful, this approach could offer a safe, home-based way for infants to outgrow egg allergy without needing hospital visits.
- What could go wrong
- This is a small, completed feasibility study, not a large trial. The results may not apply to all infants, and allergic reactions are still possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Murdoch Children's Research Institute (MCRI)
Melbourne, Victoria, 3052, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Mother's diet during pregnancy prevent peanut and egg allergies in her baby?
- Are allergy pens long enough? study measures thigh depth to find out
- AI tool aims to cut allergy misdiagnosis in primary care
- Can allergy drugs help kids tolerate peanut and more?
- Boiled cashews could be key to taming cashew allergies in kids
- Severe food allergy patients get continued access to dupilumab